Bevacizumab and Carmustine in Treating Patients With Relapsed or Progressive High-Grade Glioma

Exclusion Criteria

• •Prior intravenous or oral nitrosoureas (BCNU, CCNU) or prior VEGF targeted therapy including bevacizumab. No more than two prior chemotherapy regimens are allowed. Prior or current steroid use is allowed.
• •Evidence of CNS hemorrhage
• •Requirement for therapeutic anticoagulation
• •Any grade 3 or greater hemorrhage within the previous 28 days
• •Active inflammatory bowel disease
• •Inadequately controlled hypertension
• •Any prior history of hypertensive crisis or hypertensive encephalopathy
• •New York Heart Association Grade II or greater congestive heart failure
• •History of myocardial infarction or unstable angina within 6 months prior to study enrollment
• •History of stroke or transient ischemic attack within 6 months prior to study enrollment
• •Significant vascular disease
• •Symptomatic peripheral vascular disease
• •Evidence of bleeding diathesis or coagulopathy
• •Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to study enrollment or anticipation of need for major surgical procedure during the course of the study
• •Core biopsy or other minor surgical procedure, excluding placement of a vascular access device, within 7 days prior to study enrollment
• •History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months prior to study enrollment
• •Serious, non-healing wound, ulcer, or bone fracture
• •Proteinuria at screening
• •Pregnant (or lactating). Use of effective means of contraception in subjects of child-bearing potential
• •Prior organ transplantation
• •Known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies
• •Known acquired immune deficiency syndrome (AIDS) or HIV positive status